Skip to main content
Home > BioCentury on BioBusiness > Strategy

Chronological Index of : Strategy

 Current Issue
  • Box: Getting to 4.2

    Shire goes vertical Getting to 4.2 Shire plc's takeout price of $4.2 billion for ViroPharma Inc. is almost 10x the biotech's annual revenues, far above both the industry norm of 5-7x and a recent specialty comp. But…

    Published on 11/18/2013
  • Figure: Shire-ViroPharma sales

    Shire goes vertical Shire-ViroPharma sales Based on consensus estimates, combined product sales for Shire plc (LSE:SHP; NASDAQ:SHPG) and ViroPharma Inc. (NASDAQ:VPHM) are expected to be about $5.2 billion in 2013. …

    Published on 11/18/2013
  • Table: Rare disease pipeline

    Shire goes vertical Rare disease pipeline The acquisition of ViroPharma Inc. (NASDAQ:VPHM) would add up to three new compounds to the rare disease pipeline of Shire plc (LSE:SHP; NASDAQ:SHPG). Not counting line …

    Published on 11/18/2013
  • BMS reaches pivot point

    Why Bristol-Myers dropping discovery in diabetes, HCV, paring back neurology

    Bristol-Myers is narrowing its focus by dropping discovery in several crowded and/or particularly difficult areas while expanding in places where it has experienced recent success.

    Published on 11/18/2013
  • Box: Past as prologue

    New York translation Past as prologue Before his appointment as head of Roche's Pharma Research & Early Development organization in April, John Reed was no stranger to fostering collaborations between preclinical …

    Published on 11/11/2013
  • Table: pRED pipeline

    New York translation pRED pipeline Roche's Pharma Research & Early Development (pRED) organization is managing the Phase I and Phase II development of 23 new molecular entities (NMEs), while the company's Pharma …

    Published on 11/11/2013
  • New York translation

    Roche's new translational center will let pRED conduct early POC studies

    Roche's new Translational Clinical Research Center in New York will enable its pRED organization to get early proof of concept in humans.

    Published on 11/11/2013
  • Teva blinks

    Levin's abrupt exit from Teva leaves board responsible for company's turnaround

    The abrupt departure of President and CEO Jeremy Levin leaves Teva's board responsible for restoring the company's ailing business and assuaging investors who had bought into Levin's plan to transform the company.

    Published on 11/4/2013
  • Figure: Teva ownership

    Teva blinks Teva ownership Based on ownership stakes in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), disclosed via 13-F filings, U.S. investors hold almost 38% of the company. Data are publicly disclosed for 423…

    Published on 11/4/2013
  • Figure: Teva revenues by region

    Teva blinks Teva revenues by region Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) reported $20.3 billion in revenues in 2012. The U.S. accounts for about half the total; Israel was 3%. Source: Teva 20-F filing

    Published on 11/4/2013
  • Table: Teva board

    Teva blinks Teva board While the overwhelming majority of employees and sales come from outside Israel, all but three of 15 board members at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) are Israeli. About half …

    Published on 11/4/2013
  • Table: Teva deals

    Teva blinks Teva deals During the 18 months Jeremy Levin served as president and CEO, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) disclosed only six smallish pipeline-building deals. By comparison, Levin …

    Published on 11/4/2013
  • Table: Teva key hires

    Teva blinks Teva key hires In response to questions from analysts, Chairman Phillip Frost said he expects to retain key hires made during the tenure of Jeremy Levin as president and CEO of Teva Pharmaceutical …

    Published on 11/4/2013
  • Vaccine velocity

    Why GSK, Sanofi Pasteur joined the Gates Vaccine Discovery Partnership

    GSK and Sanofi Pasteur are the first two takers in the Gates Foundation's Vaccine Discovery Partnership initiative, which aims to speed vaccine development by working directly with pharmas.

    Published on 11/4/2013
  • Playing in the gap

    How Evotec's work with academics supports AstraZeneca kidney disease deal

    Evotec says its kidney disease deal with AstraZeneca is leveraging the biotech's ability to bridge the widening preclinical drug discovery gap between academia and pharma.

    Published on 10/28/2013
  • MedImmune's warheads

    How MedImmune acquisition of Spirogen provides complete tool set for ADCs

    AstraZeneca's latest duo of deals, with Spirogen and ADC Therapeutics, gives the pharma's MedImmune unit all the tools it needs to build out in the antibody-drug conjugate space.

    Published on 10/21/2013
  • Figure: Merck R&D comps

    Reviving Merck Merck R&D comps Among big pharmas valued from $100-$200 billion, Merck & Co. Inc. (NYSE:MRK) had the highest R&D spend as a percent of revenues at 17% in 2012. In absolute terms, Merck spent $7.9 …

    Published on 10/14/2013
  • Figure: Merck's late-stage pipeline

    Reviving Merck Merck's late-stage pipeline Merck & Co. Inc. (NYSE:MRK) restructured R&D organization will focus on four areas: acute hospital care, cancer, diabetes and vaccines, as well as specific programs in …

    Published on 10/14/2013
  • Table: Merck's platform deals

    Reviving Merck Merck's platform deals As part of its R&D restructuring, Merck & Co. Inc. (NYSE:MRK) said it would focus on four therapeutic areas - oncology, acute hospital care, vaccines and diabetes - and reduce …

    Published on 10/14/2013
  • Reviving Merck

    Why it will take years to see Perlmutter's effect on R&D at Merck

    Six months into his job as head of R&D at Merck, Roger Perlmutter has started to refocus the pharma's pipeline. But while cost-cutting is happening now, it may take at least three years before the fruits of his labor …

    Published on 10/14/2013
  • Room for improvement

    How compounds in AbbVie deals with Ablynx, Galapagos will compete on efficacy

    Products in AbbVie's deals with Ablynx and Galapagos each face marketed competition that the biotechs plan to beat through better efficacy. Both deals leave the biotechs in charge through Phase II.

    Published on 10/7/2013
  • FAKs of life

    Verastem targeting 2017 approval of lead FAK inhibitor for mesothelioma

    Verastem says last year's pipeline shakeup put it three years closer to market. It began a pivotal study this month with defactinib, a FAK inhibitor in-licensed from Pfizer for mesothelioma.

    Published on 9/30/2013
  • Figure: Partners wanted

    Deal sense at Isis Partners wanted Isis Pharmaceuticals Inc. (NASDAQ:ISIS) has 13 unpartnered compounds in development. ISIS-APOCIIIRx and ISIS-GCCRx are being developed in two indications. Sources: BCIQ: BioCentury…

    Published on 9/23/2013
  • Deal sense at Isis

    Neuro deal with Biogen reflects evolution of Isis antisense partnering strategy

    The 'Biogen 4' deal in neurology marks a new phase in the evolving partnering strategy at Isis, with broad ambitions covering an entire therapeutic area and opening the door to solutions that may not result in antisense…

    Published on 9/23/2013
  • Alzumab's (re)mission statement

    How Biocon aims to take on anti-TNF-alpha mAbs by targeting CD6

    Biocon is betting the long remission time and reduced opportunistic infections associated with its Alzumab psoriasis drug will pull doctors away from anti-TNF biologics with better efficacy.

    Published on 9/16/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993